Abstract
Omega-3 fatty acids (FAs) are effective therapies for triglyceride reduction, particularly in patients with severe hypertriglyceridemia. Recent data have demonstrated that icosapent ethyl 4 g daily also has profound benefit in cardiovascular risk reduction. This chapter summarizes the nomenclature, lipid-lowering effects, cardiovascular benefits, and mechanisms of omega-3 FAs, with a focus on their clinical utility for hypertriglyceridemia and cardiovascular risk reduction. Future directions for clinical trials are also discussed, with the hope that icosapent ethyl will be only the first of multiple therapeutic options for prevention in this class.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
